Interestingly, the biomarker analysis revealed no correlation between PD-L1 expression or tumor mutational burden and survival outcomes while an association was observed between improved PFS and a gene-expression profile signature including angiogenesis and immune-related genes [111]. This evidence concerns the gene CD274 and neoplasm.